Comparative Pharmacology
Head-to-head clinical analysis: NORTRIPTYLINE HYDROCHLORIDE versus PAMELOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTRIPTYLINE HYDROCHLORIDE versus PAMELOR.
NORTRIPTYLINE HYDROCHLORIDE vs PAMELOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nortriptyline is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminic, and alpha-adrenergic blocking properties.
Nortriptyline, the active ingredient, is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their availability in the synaptic cleft.
25 mg orally three times daily or 75 mg orally once daily at bedtime; initial dose 25 mg at bedtime, titrate up to 75-150 mg/day.
25-150 mg orally per day, typically as a single daily dose at bedtime or in divided doses; start at 25 mg 1-3 times daily and titrate gradually. Maximum 150 mg/day.
None Documented
None Documented
Terminal elimination half-life 18-56 hours (mean 28 hours); steady-state reached in 5-7 days.
Mean terminal elimination half-life is 18-24 hours (range 13-40 hours) in adults; prolonged in elderly and hepatic impairment (up to 60 hours). Steady-state achieved in 4-5 days.
Primarily renal (70% as metabolites, <5% unchanged) and fecal (30% via biliary elimination).
Primarily renal (approximately 70% as metabolites, 40-50% as glucuronide conjugates, 20-30% as free or conjugated nortriptyline; <5% unchanged), with 20-30% biliary/fecal elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant